Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Advances in Treatment for Hepatobiliary and Pancreatic Cancers: Multi-Disciplinary Strategies...
share announcement

Advances in Treatment for Hepatobiliary and Pancreatic Cancers: Multi-Disciplinary Strategies and Outcome Evaluation

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 4669

Special Issue Editors

Prof. Dr. Chun-Nan Yeh

E-Mail Website
Guest Editor
Chang Gung Memorial Hospital, Taipei, Taiwan
Interests: hepatobiliary and pancreatic surgery; minimal invasive GI surgery; gastrointestinal stromal tumor; translational research of HBP cancer
Special Issues, Collections and Topics in MDPI journals
Dr. Shang-Yu Wang

E-Mail Website
Guest Editor
GIST Team, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan
Interests: hepatobiliary and pancreatic surgery; minimal invasive GI surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hepatobiliary and pancreatic (HBP) cancers often have dismal outcomes, although several breakthroughs, including targeted therapies, advances in immuno-oncology, and newly developed systemic treatment, are now applied clinically. With advances in medical treatment, surgery is still crucial under most circumstances and provides the best chance for curing the malignancy. In addition to surgery, improvements in other local ablation therapies may also provide therapeutic benefits. Nowadays, many multidisciplinary teams are focusing on this issue, improving the treatment outcome for patients with HBP cancers.

We are pleased to invite you to contribute your work and research results to this Special Issue, which aims to improve treatment outcomes and the quality of patient care in HBP cancer management. Original research articles and reviews are welcome. Research areas of focus may include clinical, basic, and translational studies. We look forward to receiving your contributions.

Prof. Dr. Chun-Nan Yeh
Dr. Shang-Yu Wang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liver cancer
  • hepatocellular carcinoma (HCC)
  • biliary cancer
  • cholangiocarcinoma, pancreatic cancer
  • pancreatectomy
  • chemotherapy
  • radiofrequency ablation (RFA)
  • immuno-oncology
  • hepatectomy

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1139 KiB  
Article
Characterization of Salivary and Plasma Metabolites as Biomarkers for HCC: A Pilot Study
by Courtney E. Hershberger, Roma Raj, Arshiya Mariam, Nihal Aykun, Daniela S. Allende, Mark Brown, Federico Aucejo and Daniel M. Rotroff
Cancers 2023, 15(18), 4527; https://doi.org/10.3390/cancers15184527 - 12 Sep 2023
Cited by 1 | Viewed by 1297
Abstract
(1) Background: The incidence of hepatocellular carcinoma (HCC) is rising, and current screening methods lack sensitivity. This study aimed to identify distinct and overlapping metabolites in saliva and plasma that are significantly associated with HCC. (2) Methods: Saliva samples were collected from 42 [...] Read more.
(1) Background: The incidence of hepatocellular carcinoma (HCC) is rising, and current screening methods lack sensitivity. This study aimed to identify distinct and overlapping metabolites in saliva and plasma that are significantly associated with HCC. (2) Methods: Saliva samples were collected from 42 individuals (HCC = 16, cirrhosis = 12, healthy = 14), with plasma samples from 22 (HCC = 14, cirrhosis = 2, healthy = 6). We performed untargeted mass spectrometry on blood and plasma, tested metabolites for associations with HCC or cirrhosis using a logistic regression, and identified enriched pathways with Metaboanalyst. Pearson’s correlation was employed to test for correlations between salivary and plasma metabolites. (3) Results: Six salivary metabolites (1-hexadecanol, isooctanol, malonic acid, N-acetyl-valine, octadecanol, and succinic acid) and ten plasma metabolites (glycine, 3-(4-hydroxyphenyl)propionic acid, aconitic acid, isocitric acid, tagatose, cellobiose, fucose, glyceric acid, isocitric acid, isothreonic acid, and phenylacetic acid) were associated with HCC. Malonic acid was correlated between the paired saliva and plasma samples. Pathway analysis highlighted deregulation of the ‘The Citric Acid Cycle’ in both biospecimens. (4) Conclusions: Our study suggests that salivary and plasma metabolites may serve as independent sources for HCC detection. Despite the lack of correlation between individual metabolites, they converge on ‘The Citric Acid Cycle’ pathway, implicated in HCC pathogenesis. Full article
(This article belongs to the Special Issue Advances in Treatment for Hepatobiliary and Pancreatic Cancers: Multi-Disciplinary Strategies and Outcome Evaluation)
►▼ Show Figures

Figure 1

9 pages, 1232 KiB  
Article
Diagnostic Yield of Repeat Endoscopic Ultrasound-Guided Fine Needle Biopsy for Solid Pancreatic Lesions
by Baptiste Camus, Anna Pellat, Alexandre Rouquette, Ugo Marchese, Anthony Dohan, Arthur Belle, Einas Abou Ali, Stanislas Chaussade, Romain Coriat and Maximilien Barret
Cancers 2023, 15(14), 3745; https://doi.org/10.3390/cancers15143745 - 24 Jul 2023
Cited by 3 | Viewed by 1199
Abstract
Patients and methods: we performed a retrospective case-control study, including cases with repeat EUS FNB for a solid pancreatic lesion, matched on a 1:2 ratio on age, sex, tumor location and presence of chronic pancreatitis with cases diagnosed on the first EUS FNB. [...] Read more.
Patients and methods: we performed a retrospective case-control study, including cases with repeat EUS FNB for a solid pancreatic lesion, matched on a 1:2 ratio on age, sex, tumor location and presence of chronic pancreatitis with cases diagnosed on the first EUS FNB. Results: thirty-four cases and 68 controls were included in the analysis. Diagnostic accuracies were 80% and 88% in the repeat and single EUS FNB groups, respectively (p = 0.824). The second EUS FNB had a sensitivity of 80%, a specificity of 75%, a positive predictive value of 96%, and a negative predictive value of 33%. Of the 34 patients in the repeat EUS FNB group, 25 (74%) had a positive diagnosis with the second EUS FNB, 4 (12%) after surgery due to a second negative EUS FNB, 4 (12%) during clinical follow-up, and 1 (3%) after a third EUS FNB. Of the 25 patients diagnosed on the repeat EUS FNB, 17 (68%) had pancreatic adenocarcinomas, 2 (8%) neuroendocrine tumors, 2 (8%) other autoimmune pancreatitis, 2 (8%) chronic pancreatitis nodules, 1 (4%) renal cancer metastasis, and 1 (4%) other malignant diagnostic. There were no complications reported after the second EUS FNB in this study. Conclusion: repeat EUS FNB made a diagnosis in three fourths of patients with solid pancreatic lesions and a first negative EUS FNB, with 26% of benign lesions. This supports the repetition of EUS FNB sampling in this clinical situation. Full article
(This article belongs to the Special Issue Advances in Treatment for Hepatobiliary and Pancreatic Cancers: Multi-Disciplinary Strategies and Outcome Evaluation)
►▼ Show Figures

Figure 1

Review

Jump to: Research

23 pages, 778 KiB  
Review
Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma: From Pathogenesis to Diagnostic and Surveillance Strategies
by Elisa Catanzaro, Enrico Gringeri, Patrizia Burra and Martina Gambato
Cancers 2023, 15(20), 4947; https://doi.org/10.3390/cancers15204947 - 11 Oct 2023
Cited by 3 | Viewed by 1769
Abstract
Cholangiocarcinoma (CCA) is the most common malignancy in patients with primary sclerosing cholangitis (PSC), accounting for 2–8% of cases and being the leading cause of death in these patients. The majority of PSC-associated CCAs (PSC-CCA) develop within the first few years after PSC [...] Read more.
Cholangiocarcinoma (CCA) is the most common malignancy in patients with primary sclerosing cholangitis (PSC), accounting for 2–8% of cases and being the leading cause of death in these patients. The majority of PSC-associated CCAs (PSC-CCA) develop within the first few years after PSC diagnosis. Older age and male sex, as well as concomitant inflammatory bowel disease (IBD) or high-grade biliary stenosis, are some of the most relevant risk factors. A complex combination of molecular mechanisms involving inflammatory pathways, direct cytopathic damage, and epigenetic and genetic alterations are involved in cholangiocytes carcinogenesis. The insidious clinical presentation makes early detection difficult, and the integration of biochemical, radiological, and histological features does not always lead to a definitive diagnosis of PSC-CCA. Surveillance is mandatory, but current guideline strategies failed to improve early detection and consequently a higher patient survival rate. MicroRNAs (miRNAs), gene methylation, proteomic and metabolomic profile, and extracellular vesicle components are some of the novel biomarkers recently applied in PSC-CCA detection with promising results. The integration of these new molecular approaches in PSC diagnosis and monitoring could contribute to new diagnostic and surveillance strategies. Full article
(This article belongs to the Special Issue Advances in Treatment for Hepatobiliary and Pancreatic Cancers: Multi-Disciplinary Strategies and Outcome Evaluation)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop